Related Experiment Videos
[Anti-platelet therapy in ischemic cerebrovascular disorder--clinical and hematological study]
Insights
Anti-platelet therapy helped prevent recurrent ischemic cerebrovascular disorders (ICVD) in most patients. Shortened platelet survival time, a marker of clotting risk, improved with treatment, suggesting its value in guiding therapy.
Area of Science:
- Cardiovascular Medicine
- Neurology
- Hematology
Context:
- Ischemic cerebrovascular disorders (ICVD) pose significant health risks.
- Anti-platelet therapy is a common treatment for ICVD.
- Predicting treatment efficacy and recurrence risk in ICVD patients remains challenging.
Purpose:
- To evaluate the effectiveness of anti-platelet therapy (Aspirin + Dipyridamole) in preventing ICVD recurrence.
- To investigate the relationship between platelet function (aggregability and survival time) and ICVD recurrence.
- To assess the utility of platelet survival time measurement in guiding anti-platelet therapy.
Summary:
- A study involving 51 patients with ICVD treated with Aspirin and Dipyridamole showed a low recurrence rate (10/51).
- Platelet survival time was found to be shortened in a majority of patients (79%) prior to treatment, indicating increased clotting risk.
- Treatment with anti-platelet drugs prolonged platelet survival time in 90% of patients, correlating with a lack of recurrence in 78% of these cases.
- No significant differences in risk factors or clinical findings were observed between patients with and without recurrence.
Impact:
- Platelet survival time measurement may serve as a valuable biomarker for indicating and monitoring anti-platelet therapy in ICVD patients.
- Findings suggest that improved platelet survival time is associated with reduced ICVD recurrence.
- This research could lead to more personalized anti-platelet treatment strategies for cerebrovascular disorders.
Abstract:
Anti-platelet therapy (Aspirin 250 mg/every other day approximately 1000 mg/day + Dipyridamole 150 mg/day) was performed on 51 patients with ischemic cerebrovascular disorders (ICVD). Among these patients, 41 cases showed no recurrence of ICVD attack, whereas the remaining 10 cases had re-attacks. These 2 groups were compared from the viewpoint of various risk factors and other clinical findings: e.g. CT scan and angiographic appearance. But there was no statistically significant difference between them. Platelet aggregability and platelet survival time were examined in twenty-eight patients out of cases. We used a simple nonradioisotope technic for the determination of platelet survival time. Platelet survival time was shortened in 22 of 28 (79%) patients. On the other hand, platelet aggregability was found to have no definite tendency. In 9 of 10 cases, platelet survival time was revealed to be prolonged several months after administration of anti-platelet drugs. There was no re-attack in 7 of these 9 patients. Some reports also showed that platelet survival time was shortened in various thromboembolism and recovered by anti-platelet drugs. Measurement of platelet survival time is thought to be an important method as to the indication and the monitoring of anti-platelet therapy.